Comparison of Glucosamine Sulfate and a Polyherbal Supplement for the Relief of Osteoarthritis of the Knee: a Randomized Controlled Trial [ISRCTN25438351]

Overview

Journal BMC Complement Altern Med

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2007 Nov 2

PMID 17974032

Citations 10

Authors

Komal Mehta

Jayesh Gala

Surendra Bhasale

Sattayasheel Naik

Millind Modak

Harshad Thakur

Nivedita Deo

Mark J S Miller

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy and safety of a dietary supplement derived from South American botanicals was compared to glucosamine sulfate in osteoarthritis subjects in a Mumbai-based multi-center, randomized, double-blind study.

Methods: Subjects (n = 95) were screened and randomized to receive glucosamine sulfate (n = 47, 1500 mg/day) or reparagen (n = 48, 1800 mg/day), a polyherbal consisting of 300 mg of vincaria (Uncaria guianensis) and 1500 mg of RNI 249 (Lepidium meyenii) administered orally, twice daily. Primary efficacy variable was response rate based on a 20% improvement in WOMAC pain scores. Additional outcomes were WOMAC scores for pain, stiffness and function, visual analog score (VAS) for pain, with assessments at 1, 2, 4, 6 and 8 weeks. Tolerability, investigator and subject global assessments and rescue medication consumption (paracetamol) were measured together with safety assessments including vital signs and laboratory based assays.

Results: Subject randomization was effective: age, gender and disease status distribution was similar in both groups. The response rates (20% reduction in WOMAC pain) were substantial for both glucosamine (89%) and reparagen (94%) and supported by investigator and subject assessments. Using related criteria response rates to reparagen were favorable when compared to glucosamine. Compared to baseline both treatments showed significant benefits in WOMAC and VAS outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment protocol (45-62% reduction in WOMAC or VAS scores). Tolerability was excellent, no serious adverse events were noted and safety parameters were unchanged. Rescue medication use was significantly lower in the reparagen group (p < 0.01) at each assessment period. Serum IGF-1 levels were unaltered by treatments.

Conclusion: Both reparagen and glucosamine sulfate produced substantial improvements in pain, stiffness and function in subjects with osteoarthritis. Response rates were high and the safety profile was excellent, with significantly less rescue medication use with reparagen. Reparagen represents a new natural productive alternative in the management of joint health.

Trial Registration: Current Controlled Trials ISRCTN25438351.

Citing Articles

Non-invasive prediction of maca powder adulteration using a pocket-sized spectrophotometer and machine learning techniques.

Zaukuu J, Adams Z, Donkor-Boateng N, Mensah E, Bimpong D, Amponsah L Sci Rep. 2024; 14(1):10426.

PMID: 38714752 PMC: 11076633. DOI: 10.1038/s41598-024-61220-1.

Dietary Interventions with Polyphenols in Osteoarthritis: A Systematic Review Directed from the Preclinical Data to Randomized Clinical Studies.

Valsamidou E, Gioxari A, Amerikanou C, Zoumpoulakis P, Skarpas G, Kaliora A Nutrients. 2021; 13(5).

PMID: 33922527 PMC: 8145539. DOI: 10.3390/nu13051420.

Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?.

Vannabouathong C, Zhu M, Chang Y, Bhandari M Clin Med Insights Arthritis Musculoskelet Disord. 2021; 14:11795441211002492.

PMID: 33795939 PMC: 7970188. DOI: 10.1177/11795441211002492.

Nutraceutical supplements in management of pain and disability in osteoarthritis: a systematic review and meta-analysis of randomized clinical trials.

Aghamohammadi D, Dolatkhah N, Bakhtiari F, Eslamian F, Hashemian M Sci Rep. 2020; 10(1):20892.

PMID: 33262447 PMC: 7708648. DOI: 10.1038/s41598-020-78075-x.

Oral herbal therapies for treating osteoarthritis.

Cameron M, Chrubasik S Cochrane Database Syst Rev. 2014; (5):CD002947.

PMID: 24848732 PMC: 4494689. DOI: 10.1002/14651858.CD002947.pub2.

References

Haupt J, Frisbie D, McIlwraith C, Robbins P, Ghivizzani S, Evans C . Dual transduction of insulin-like growth factor-I and interleukin-1 receptor antagonist protein controls cartilage degradation in an osteoarthritic culture model. J Orthop Res. 2004; 23(1):118-26. DOI: 10.1016/j.orthres.2004.06.020. View

Verschure P, Van Noorden C, van Marle J, van den Berg W . Articular cartilage destruction in experimental inflammatory arthritis: insulin-like growth factor-1 regulation of proteoglycan metabolism in chondrocytes. Histochem J. 1996; 28(12):835-57. DOI: 10.1007/BF02331388. View

Thompson J, Zhang X, Liu X, Mannick E, Sadowska-Krowicka H, Charbonnet R . Antiinflammatory actions of cat's claw: the role of NF-kappaB. Aliment Pharmacol Ther. 1999; 12(12):1279-89. DOI: 10.1046/j.1365-2036.1998.00424.x. View

Muniyappa R, Karne R, Hall G, Crandon S, Bronstein J, Ver M . Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. Diabetes. 2006; 55(11):3142-50. DOI: 10.2337/db06-0714. View

Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G . Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005; 365(9458):475-81. DOI: 10.1016/S0140-6736(05)17864-7. View

Uitterlinden E, Jahr H, Koevoet J, Jenniskens Y, Bierma-Zeinstra S, Degroot J . Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage. 2005; 14(3):250-7. DOI: 10.1016/j.joca.2005.10.001. View

Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz J, Rozenberg S . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage. 1998; 6 Suppl A:25-30. DOI: 10.1016/s1063-4584(98)80008-3. View

Gonzales G, Cordova A, Gonzales C, Chung A, Vega K, Villena A . Lepidium meyenii (Maca) improved semen parameters in adult men. Asian J Androl. 2001; 3(4):301-3. View

Clegg D, Reda D, Harris C, Klein M, ODell J, Hooper M . Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006; 354(8):795-808. DOI: 10.1056/NEJMoa052771. View

10.

Sandoval M, Charbonnet R, Okuhama N, Roberts J, Krenova Z, Trentacosti A . Cat's claw inhibits TNFalpha production and scavenges free radicals: role in cytoprotection. Free Radic Biol Med. 2000; 29(1):71-8. DOI: 10.1016/s0891-5849(00)00327-0. View

11.

Vuppalanchi R, Liangpunsakul S, Chalasani N . Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol. 2006; 102(3):558-62. DOI: 10.1111/j.1572-0241.2006.01019.x. View

12.

Reginster J, Deroisy R, Rovati L, Lee R, Lejeune E, Bruyere O . Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001; 357(9252):251-6. DOI: 10.1016/S0140-6736(00)03610-2. View

13.

Cappola A, Xue Q, Ferrucci L, Guralnik J, Volpato S, Fried L . Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab. 2003; 88(5):2019-25. DOI: 10.1210/jc.2002-021694. View

14.

Christgau S, Henrotin Y, Tanko L, Rovati L, Collette J, Bruyere O . Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol. 2004; 22(1):36-42. View

15.

BACH G, Haase W, Rovati L, Setnikar I . Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994; 2(1):61-9. DOI: 10.1016/s1063-4584(05)80007-x. View

16.

Miller M, Mehta K, Kunte S, Raut V, Gala J, Dhumale R . Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial [ISRCTN38432711]. J Inflamm (Lond). 2005; 2:11. PMC: 1276811. DOI: 10.1186/1476-9255-2-11. View

17.

Liacini A, Sylvester J, Li W, Huang W, Dehnade F, Ahmad M . Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res. 2003; 288(1):208-17. DOI: 10.1016/s0014-4827(03)00180-0. View

18.

Grainger R, Cicuttini F . Medical management of osteoarthritis of the knee and hip joints. Med J Aust. 2004; 180(5):232-6. DOI: 10.5694/j.1326-5377.2004.tb05892.x. View

19.

Towheed T, Maxwell L, Anastassiades T, Shea B, Houpt J, Robinson V . Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005; (2):CD002946. PMC: 8459392. DOI: 10.1002/14651858.CD002946.pub2. View

20.

Denti L, Annoni V, Cattadori E, Salvagnini M, Visioli S, Merli M . Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med. 2004; 117(5):312-7. DOI: 10.1016/j.amjmed.2004.02.049. View